Literature DB >> 15693848

Establishment and characterization of a KIT-positive and stem cell factor-producing cell line, KTHOS, derived from human osteosarcoma.

Toshiaki Hitora1, Tetsuji Yamamoto, Toshihiro Akisue, Takashi Marui, Tetsuya Nakatani, Teruya Kawamoto, Keiko Nagira, Shinichi Yoshiya, Masahiro Kurosaka.   

Abstract

Osteosarcoma is a malignant bone tumor that commonly affects adolescents and young adults. In the present study a human osteosarcoma cell line, KTHOS, was established from a primary osteosarcoma lesion in the distal femur of a 16-year-old girl. After 106 passages, the KTHOS cell line retained the biological characteristics of osteosarcoma. The KTHOS cells had spindle to pleomorphic cytoplasm with round to ovoid nuclei containing multiple prominent nucleoli, as expected based on the mesodermic origin of osteoblasts. The KTHOS cells were immunoreactive for osteocalcin, osteonectin, stem cell factor (SCF), and KIT (CD117). Reverse transcriptase-polymerase chain reaction indicated that the KTHOS cell line expressed mRNA for SCF and KIT. The KTHOS cells produced relatively high amounts of soluble SCF as determined by enzyme-linked immunosorbent assay. The results suggest that cell proliferation of the KTHOS cell line might be involved in autocrine and/or paracrine loops of the SCF/KIT signaling system. The KTHOS cell line is a novel human osteosarcoma cell line that releases SCF and expresses KIT. This cell line can be used for studies to explore the mechanisms for oncogenesis of human osteosarcomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15693848     DOI: 10.1111/j.1440-1827.2005.01787.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  1 in total

1.  Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours.

Authors:  Y Inagaki; E Hookway; K A Williams; A B Hassan; U Oppermann; Y Tanaka; E Soilleux; N A Athanasou
Journal:  Clin Sarcoma Res       Date:  2016-08-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.